Program Director/Principal Investigator (Last, First, Middle):
BIOGRAPHICAL SKETCH
Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
Richard C. Harvey, Ph.D.
Research Professor, Pathology
eRA COMMONS USER NAME (credential, e.g., agency login)
rharvey
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and
residency training if applicable.)
DEGREE
INSTITUTION AND LOCATION
MM/YY
FIELD OF STUDY
(if applicable)
Haverford College Haverford, PA
University of Pennsylvania Philadelphia, PA
Undergrad
Ph.D.
1977-1981
1983-1989
University of California – San Francisco/VAMC
San Francisco, CA
Postdoctoral
Fellow
1989-1992
Biology
Genetics (Molecular
genetics of leukemia)
Identification and
characterization of
oncogenes
A. Personal Statement
B. Positions and Honors
1989-1992
Postdoctoral fellow, University of California-San Francisco/VAMC, Department of
Hematology, San Francisco, CA
1992-1999 Staff Scientist, Gen-Probe Incorporated, San Diego, CA
1999-2002 Manager of Molecular Pathology, DAKO Corporation, Carpinteria, CA
2002-2010 Research Associate Professor of Pathology and Scientific Director of the Center for
Molecular and Cellular Diagnostics, University of New Mexico, Albuquerque, NM
2010-present Research Professor of Pathology and Scientific Director of the Center for Molecular and Cellular
Diagnostics, University of New Mexico, Albuquerque, NM
Memberships:
1995 – 2002
1997 – present
1997 – present
Association for Molecular Pathology
American Association for Cancer Research
American Society of Hematology
C. Selected Peer-reviewed Publications
1. Mullighan CG, Collins-Underwood JR, Phillips LA, Loudin MG, Liu W, Zhang J, Ma J, Coustan-Smith E,
Harvey RC, Willman CL, Mikhail FM, Meyer J, Carroll AJ, Williams RT, Cheng J, Heerema NA, Basso G,
Pession A, Pui CH, Raimondi SC, Hunger SP, Downing JR, Carroll WL, Rabin KR. (2009) Rearrangement
of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009
Nov;41(11):1243-6. Epub 2009 Oct 18.
2. Mullighan CG, Su X, Zhang J, Radke I, Phillips LAA, Miller CB, Ma J, Liu W, Cheng C, Shulman BA,
Harvey RC, Chen IM, Clifford RJ, Carroll WL, Reaman G, Bowman WP, Devidas M, Gerhard DS, Wang
W, Relling MV, Shurtleff SA, Campana D, Borowitz MJ, Pui CH, Smith M, Hunger SP, Willman CL, and
Downing JR. 2009. Deletion of IKZF1 (IKAROS) is associated with poor prognosis in acute lymphoblastic
leukemia. New England J Medicine. 2009 Jan 29; 360(5):470-480. PMID: 19129520.
3. Mullighan CG, Zhang J, Harvey RC, Schulman BA, Phillips LA, Su X, Devidas M, Atlas SR, Chen IM,
Clifford R, Gerhard D, Carroll WL, Reaman GH, Smith M, Downing JR, Hunger SP, and Willman CL. 2009.
JAK mutations in high risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2009. Jun 9;
106(23):9414-8. PMID: 19470474.
PHS 398/2590 (Rev. 06/09)
Page
Biographical Sketch Format Page
Program Director/Principal Investigator (Last, First, Middle):
4. Harvey RC, Mullighan CG, Chen IM, Wharton W, Mikhail FM, Carroll AJ, Kang H, Liu W, Dobbin KK, Smith
MA, Carroll WL, Devidas M, Bowman WP, Camitta BM, Reaman GH, Hunger SP, Downing JR, and
Willman CL. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1,
Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.
Blood. 2010. Jul 1; 115(26):5312-21. Epub. Feb 4. PMID: 20139093.
5. Kang H, Chen IM, Wilson CS, Bedrick EJ, Harvey RC, Atlas SR, Hunger SP, Devidas M, Wang X,
Murphy M, K Ar, Wharton W, Borowitz MJ, Bowman WP, Bhojwani D, Carroll WL, Camitta B, Reaman GH,
and Willman CL. Gene expression classifiers for relapse free survival and minimal residual disease
improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia.
Blood. 2010 Feb 18;115(7): 1394-405. PMID: 19880498.
6. Harvey RC, Wang X, Dobbin KK, Davidson GS, Bedrick EJ, Chen IM, Atlas SR, Kang H, K Ar, Wilson CS,
Wharton W, Murphy M, Devidas M, Carroll AJ, Borowitz MJ, Bowman WP, Mullighan CG, Downing JR,
Yang JJ, Carroll WL, Camitta B, Reaman GH, Smith M, Hunger SP, and Willman CL. Identification of
novel cluster groups in pediatric high risk B-precursor acute lymphoblastic leukemia by gene expression
profiling: Correlation with genome-wide DNA copy number alterations, clinical characteristics, and
outcome. Blood. 2010 Dec. 2; 116(23):4874-64. PMID: 20699438
7. Meng X, Matlawska-Wasowska K, Girodon F, Mazel T, Willman CL, Atlas S, Chen IM, Harvey RC, Hunger
SP, Ness SA, Winter S, and Wilson BS. GSI-I (Z-LLNle-CHO) inhibits gamma-secretase and the
proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia. 2011, Leukemia,
Jul;25(7):1135-46. PMCID: PMC3170956
8. Zhang J, Mullighan CG, Harvey RC, Wu G, Chen X, Edmonson M, Buetow KH, Carroll WL, Chen I-M,
Devidas M, Gerhard DS, Loh ML, Reaman GH, Relling MV, Camitta BM, Bowman WP, Smith MA, Willman
CL#, Downing JR#, and Hunger SP.# (# senior authors who contributed equally to the work).
Mutations in the RAS signaling, B-cell development, TP53/RB1, and JAK signaling pathways are common
in high risk B-precursor childhood acute lymphoblastic leukemia: A report from the Children’s Oncology
Group NCI TARGET Project. 2011. Blood. 118(11):3080-7. PMCID: PMC3175785
9. Kang H, Wilson CS, Harvey RC, Chen IM, Murphy MH, Atlas SR, Bedrick EJ, Devidas M, Carroll AJ,
Robinson BW, Stam RW, Valsecchi MG, Pieters R, Heerema NA, Hilden JM, Felix CA, Reaman GH,
Camitta B, Winick N, Carroll WL, Dreyer ZE, Hunger SP, Willman CL. Gene expression profiles predictive
of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study. Blood
119:1872-81 (2012)
10. I-Ming Chen, Richard C. Harvey, Charles G. Mullighan, Julie M. Gastier-Foster, Walker Wharton, Huining
Kang, Michael J. Borowitz, Bruce M. Camitta, Andrew J. Carrolll, Meenakshi Devidas, D. Jeanette Pullenm
Debbie Payne-Turner, Sarah K. Tasian, Shalini Reshmi, Catherine E. Cottrell, Gregory H. Reaman, W.
Paul Bowman, William L. Carroll, Mingon L. Loh, Naomi J. Winick, Stephen P. Hunger, and Cheryl L.
Willman. Outcome modeling with CRLF2, IKZF1, JAK, and Minimal Residual Disease in Pediatric Acute
Lymphoblastic Leukemia: A Children’s Oncology Group Study. Blood 119: 3512-3522(2012).
11. Tasian SK, Doral MY, Borowitz MJ, Wood BL, Chen IM, Harvey RC, Gastier-Foster JM, Willman CL,
Hunger SP, Mullighan CG, Loh ML. Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human
CRLF2-rearranged B-precursor acute lymphoblastic leukemia. Blood. 2012 Jul 26;120(4):833-42. doi:
10.1182/blood-2011-12-389932. Epub 2012 Jun 8. PubMed PMID: 22685175; PubMed Central PMCID:
PMC3412346.
12. Gallagher RE, Moser BK, Racevskis J, Poiré X, Bloomfield CD, Carroll AJ, Ketterling RP, Roulston D,
Schachter-Tokarz E, Zhou DC, Chen IM, Harvey R, Koval G, Sher DA, Feusner JH, Tallman MS, Larson
RA, Powell BL, Appelbaum FR, Paietta E, Willman CL, Stock W. Treatment-influenced associations of
PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed
acutepromyelocytic leukemia. Blood. 2012 Sep 6;120(10):2098-108. PMCID: PMC3437597.
13. Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X, Chen SC, Payne-Turner D, Churchman ML,
Harvey RC, Chen X, Kasap C, Yan C, Becksfort J, Finney RP, Teachey DT, Maude SL, Tse K, Moore R,
Jones S, Mungall K, Birol I, Edmonson MN, Hu Y, Buetow KE, Chen IM, Carroll WL, Wei L, Ma J, Kleppe
M, Levine RL, Garcia-Manero G, Larsen E, Shah NP, Devidas M, Reaman G, Smith M, Paugh SW, Evans
WE, Grupp SA, Jeha S, Pui CH, Gerhard DS, Downing JR, Willman CL, Loh M, Hunger SP, Marra MA,
Mullighan CG. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute
lymphoblastic leukemia. Cancer Cell. 2012 Aug 14;22(2):153-66. PMCID: PMC3422513.
PHS 398/2590 (Rev. 06/09)
Page
Biographical Sketch Format Page
Program Director/Principal Investigator (Last, First, Middle):
14. Maude SL, Tasian SK, Vincent T, Hall JW, Sheen C, Roberts KG, Seif AE, Barrett DM, Chen IM, Collins
JR, Mullighan CG, Hunger SP, Harvey RC, Willman CL, Fridman JS, Loh ML, Grupp SA, Teachey DT.
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood.
2012 Oct 25;120(17):3510-8. PMCID: PMC3482861
15. Loh ML, Zhang J, Harvey RC, Roberts K, Payne-Turner D, Kang H, Wu G, Chen X, Becksfort J,
Edmonson M, Buetow KH, Carroll WL, Chen IM, Wood B, Borowitz MJ, Devidas M, Gerhard DS, Bowman
P, Larsen E, Winick N, Raetz E, Smith M, Downing JR, Willman CL, Mullighan CG, Hunger SP. Tyrosine
kinome sequencing of pediatric acute lymphoblastic leukemia: a report from The Children's Oncology
Group TARGET Project. Blood. 2012 Dec 4. [Epub ahead of print] PubMed PMID: 23212523.
D. Research Support
1 U01 CA157937-01 (Contact PI: Willman, Multi PI: Hunger)
8/1/11-7/31/16
NIH/NCI
SPECS II: Molecular Signatures for Outcome Prediction and Therapeutic Targeting in ALL
The goal of this project is to develop gene expression classifiers nanoparticle platforms to target delivery of a
variety of different cargos to acute lymphoblastic leukemia cells.
PHS 398/2590 (Rev. 06/09)
Page
Biographical Sketch Format Page